Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $167M | $119M | $260M | $366M | $398M | $334M | $301M |
| Revenue growth | — | -28.5% | 118.4% | 40.7% | 8.8% | -16.0% | -10.0% |
| Gross profit | $107M | $67.2M | $179M | $249M | $155M | $182M | $196M |
| Gross margin | 63.9% | 56.4% | 68.6% | 68.0% | 39.0% | 54.5% | 65.3% |
| Operating income | $13.5M | -$17.2M | -$39.9M | -$25.8M | -$131M | -$67.8M | -$20.8M |
| Operating margin | 8.1% | -14.4% | -15.4% | -7.1% | -32.9% | -20.3% | -6.9% |
| Net income | -$1.64M | -$29.2M | -$379M | $44.2M | -$100M | -$29.1M | -$9.52M |
| Net margin | -1.0% | -24.5% | -145.6% | 12.1% | -25.2% | -8.7% | -3.2% |
| EPS (diluted) | -$0.05 | -$0.85 | -$3.71 | -$0.23 | -$0.76 | -$0.36 | -$0.16 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.73M | -$12.4M | -$28.4M | -$107M | $21.8M | $16.1M | $37.5M |
| Capital expenditures | $8.77M | $3.50M | $11.2M | $10.8M | $3.83M | $756K | $303K |
| Free cash flow | -$7.05M | -$15.9M | -$39.6M | -$117M | $17.9M | $15.4M | $37.2M |
| Share buybacks | $0.00 | $154K | $0.00 | $160M | $30.2M | $0.00 | $0.00 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.31M | $9.49M | $902M | $568M | $523M | $370M | $233M |
| Total assets | — | $223M | $1.22B | $1.00B | $929M | $686M | $500M |
| Total liabilities | — | $253M | $917M | $836M | $870M | $634M | $439M |
| Shareholders' equity | -$1.21M | -$30.6M | $298M | $167M | $59.4M | $51.8M | $61.1M |
| Retained earnings | — | -$43.6M | -$419M | -$379M | -$479M | -$508M | -$517M |
| Shares (wtd avg diluted) | 32.1M | 34.3M | 102M | 149M | 132M | 142M | 136M |
Every figure is extracted from SkinHealth Systems Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.